Effect of Inhibition of Xenobiotic Transporter MRP5/ABCC5 on Neurite Elongation: Screening for MRP5 Inhibitors among Clinically Used Drugs

Takahiro Ishimoto,Hirofumi Yagi,Yusuke Masuo,Yukio Kato
DOI: https://doi.org/10.1124/jpet.122.173230
2023-05-19
Journal of Pharmacology and Experimental Therapeutics
Abstract:ID 17323 Poster Board 339 Aim: We have previously reported that expression of multidrug resistance associated protein 5 (MRP5/ABCC5) in murine primary cortical neurons (PCNs) is much higher than other ABCC family transporters. However, its physiological function remains uncertain. We hypothesized that inhibition of MRP5 would promote neurite elongation because MRP5 efflux the second messengers such as cGMP and cAMP, which are important modulators of neurite elongation. The present study aimed to evaluate the effect of the knockdown of MRP5 on neurite outgrowth and to screen for MRP5 inhibitors among clinically used drugs acting in the central nervous system. Methods: Protein expression of MRP5 in PCNs was examined by immunocytochemical analysis. To evaluate the effect of MRP5 knockdown on neurite elongation, a neuronal cell line Neuro2A was transfected with siRNA for Mrp5 (siMrp5), followed by counting cells with neurites longer than the cell diameter. To check the efflux activity of MRP5 in Neuro2A, we used CMFDA, which is metabolized inside the cells to become a fluorescent substrate of MRP5; Neuro2A was incubated with CMFDA, and intracellular fluorescence intensity was measured. Results and Discussion: Immunocytochemical analysis showed that MRP5 was expressed in the PCNs and Neuro2A, which are positive for the neuronal marker βIII-tubulin. Transfection with siMrp5 in Neuro2A showed significantly lower mRNA expression of Mrp5 compared to negative siRNA-treated cells. The siMrp5 transfection significantly increased the number of cells with longer neurites and mRNA expression of neurite marker gap43 compared to negative siRNA transfection. The Mrp5 knockdown increased the expression of cGMP-dependent protein kinase (PKG), whereas a PKG inhibitor KT5823 significantly suppressed the neurite elongation induced by the knockdown with a concomitant decrease in the expression of PKG. These results suggest that inhibition of MRP5 promotes neurite elongation by activating PKG. Furthermore, we performed the screening for MRP5 inhibitors among clinical drugs. Neuro2A transfected with siMrp5 showed a higher intensity of intracellular fluorescence of CMFDA metabolite during incubation with CMFDA compared to negative siRNA. In addition, a typical inhibitor for MRP5 zaprinast also increased the fluorescent intensity, confirming that the assay is useful to assess the efflux activity of MRP5. Midazolam, perampanel, and nitrazepam remarkably increased the intracellular fluorescent intensity of the CMFDA metabolite. Exposure to midazolam or perampanel significantly promoted neurite elongation in PCNs. These drugs may thus potentially affect the neurite elongation by MRP5 inhibition and would be useful for the regulation of neurite outgrowth. Further studies are needed to elucidate the detailed mechanisms and to evaluate the possible involvement of clinically used MRP5 inhibitors in neurite elongation. Conclusion: Inhibition of MRP5 promotes neurite elongation by activating PKG. Midazolam and perampanel have been found to be novel MRP5 inhibitors, which promote neurite elongation in PCNs.
pharmacology & pharmacy
What problem does this paper attempt to address?